The funds will support Immunovaccine’s RSV program advancement, including formulation of RSV antigens in DepoVax vaccine adjuvanting technology.
Immunovaccine chief executive officer John Trizzino said at present there is no vaccine against RSV.
"It is second only to influenza as a killer of vulnerable people, taking an estimated 160,000 lives around the world each year," Trizzino added.
"We are grateful to the IRAP Industrial Technology Advisors for being proactive in working with our company to assist in identifying and supporting research that is directed to the most technically challenging aspects of new product development."
Funding will allow the company to prepare for the first human trial of its DepoVax platform technology in infectious diseases.